Chimeric Therapeutics (CHM) AGM Presentation 2024 summary

Leadership and management

• Dr Rebecca McQualter appointed CEO effective 12 Nov 2024, with fixed remuneration of A$350,000 per annum.

• Leadership team has over 75 years of cell therapy experience, including backgrounds at Amgen, Novartis, Juno, Fate, Celgene, and Artiva.

Clinical pipeline and technology

• Portfolio includes 3 novel cell therapies (CHM CDH17, CHM CLTX, CHM CORE-NK) in 4 Phase 1/1b clinical trials.

• Technologies sourced from University of Pennsylvania, City of Hope, and Case Western Reserve University.

• CHM CDH17 is the only CDH17 CAR-T in clinical trials; CLTX-CAR is first-in-class for brain cancer.

Clinical results and milestones

• CORE-NK therapy showed ongoing complete response over 48 months in high-risk blood cancer with no dose-limiting toxicities.

• Combination trial with CORE-NK and TGF-B achieved complete response by day 28 in acute myeloid dysplastic syndrome.

• Multiple clinical updates and catalysts expected in the next 12 months, including new trial designs and preliminary data.